Compare JXN & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JXN | SRRK |
|---|---|---|
| Founded | 1961 | 2012 |
| Country | United States | United States |
| Employees | 3890 | N/A |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.8B |
| IPO Year | N/A | 2018 |
| Metric | JXN | SRRK |
|---|---|---|
| Price | $133.29 | $51.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $112.40 | $56.17 |
| AVG Volume (30 Days) | 608.7K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.15 | N/A |
| Revenue Next Year | $3.44 | $534.24 |
| P/E Ratio | $16.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $89.67 | $27.07 |
| 52 Week High | $137.99 | $58.49 |
| Indicator | JXN | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | N/A |
| Support Level | $102.95 | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 3.75 | 0.00 |
| MACD | 0.53 | 0.00 |
| Stochastic Oscillator | 67.98 | 0.00 |
Jackson Financial Inc helps Americans grow and protect their retirement savings and income to enable them to pursue financial freedom for life. Its retail product offerings are comprised of annuities, designed to help retail investors save for and live in retirement. Its diverse suite of annuities includes a variable, fixed index, and fixed annuities. The company manages its business through three segments: Retail Annuities, Institutional Products, and Closed Life and Annuity Blocks and Corporate and Other segments. The company generates the majority of its revenue from the Retail Annuities segment, which offers a variety of retirement income and savings products of variable annuities, registered index-linked annuities ("RILA"), fixed index annuities, fixed annuities, and payout annuities.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.